...
首页> 外文期刊>European journal of clinical pharmacology >Diuretic drug therapy monitoring in the elderly: a cohort study.
【24h】

Diuretic drug therapy monitoring in the elderly: a cohort study.

机译:老年人的利尿药物治疗监测:一项队列研究。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Because the elderly are often treated by multiple-drug regimens, their iatrogenic risks are considerably raised. However, despite the serious side-effects that diuretic agents may have in this population, SPCs (summary of product characteristics) do not specify how often serum chemistry should be monitored. This study of long-term diuretic therapy prescription and monitoring in elderly patients was conducted by the Department of Clinical Pharmacology of the Nantes teaching hospital in collaboration with the medical department of the French national health insurance scheme. METHODS: Data were extracted from the French national health insurance database. Patients were 75 years old or more and had been receiving a diuretic agent for 1 year or longer. The patients were classified into two groups: one group included those patients whose serum chemistry had been monitored at least once (electrolyte levels and/or urea and creatinine blood levels); the other group included the non-monitored patients. RESULTS: Mean patient age was 80 +/- 4.6 (SD) years. The non-monitored patients represented 22.8% of the cohort. The at-risk patients were mainly women suffering from no severe disease, treated by a single practitioner (often a general practitioner) and/or always receiving the same type of diuretic agent. CONCLUSION: Many elderly patients receiving diuretic agents do not benefit from regular serum chemistry monitoring. The prescription of serum chemistry assays is correlated to the presence of various patient-related risk factors. Recommendations should be made to help practitioners to ensure a minimal serum chemistry monitoring in all elderly patients receiving diuretics.
机译:背景:由于老年人经常接受多种药物治疗,因此其医源性风险大大增加。然而,尽管利尿剂可能在该人群中产生严重的副作用,但SPC(产品特性的概述)并未指定应多长时间监测一次血清化学反应。南特教学医院的临床药理学部与法国国家健康保险计划的医学部合作,对老年患者进行长期利尿剂治疗处方和监测的研究。方法:数据摘自法国国家健康保险数据库。患者年龄在75岁以上,并且已经接受利尿剂治疗1年或更长时间。将患者分为两类:一组包括至少监测过一次血清化学(电解质水平和/或尿素和肌酐血液水平)的患者;另一组包括非监测患者。结果:平均患者年龄为80 +/- 4.6(SD)岁。未监测的患者占同期队列的22.8%。高危患者主要是没有严重疾病的妇女,由一名执业医师(通常是全科医生)治疗和/或始终接受相同类型的利尿剂治疗。结论:许多接受利尿剂治疗的老年患者不能从定期的血清化学监测中受益。血清化学测定的处方与各种患者相关的危险因素的存在相关。应提出建议,以帮助从业人员确保对所有接受利尿剂治疗的老年患者进行最低限度的血清化学监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号